Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640337 | 0.96 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL9900580 | 0.78 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11240479 | 0.78 | RAB9A (0.76) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL9900395 | 0.77 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL28928584 | 0.77 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL520877 | 0.77 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL126657 | 0.77 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL3143526 | 0.75 | KMT2A (0.74) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11687058 | 0.75 | KMT2A (0.74) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL17749725 | 0.75 | TDP1 (0.50) | SMN1; SMN2HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003409-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-115583947-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-10 | — | — | CN | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| CN-107207493-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2017-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | NPC1 1302/4885RAB9A 1868/4885SMN1; SMN2 1340/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | NPC1 1302/4885RAB9A 1868/4885SMN1; SMN2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.